🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CONGRESS | #EHA2025 | POSTER Carmelo Carlo-Stella Humanitas Milano shares updated safety run-in data from LOTIS-5, a phase 3, randomized trial of loncastuximab tesirine with rituximab (Lonca-R) vs immunochemotherapy in patients with R/R DLBCL/HGBL (N=20). ORR was achieved by 80%

CONGRESS | #EHA2025 | POSTER Mazyar Shadman Mazyar Shadman, MD MPH @FredHutch shares the 5-year follow up from the SEQUOIA study Arm C of frontline zanubrutinib monotherapy in pts with del(17p) and treatment-naive CLL/SLL. Zanubrutinib demonstrated durable efficacy in pts with del(17p), with

CONGRESS | #EHA2025 | PRESENTATION Raul Cordoba Raul Cordoba, MD, PhD Fundación Jiménez Díaz presents the first efficacy and safety results for epcoritamab in combination with R-ICE in patients with R/R DLBCL eligible for ASCT from the EPCORE NHL-2 trial (N = 31). Epcoritamab + R-ICE

CONGRESS | #EHA2025 | PRESENTATION Yuqin Song, Peking University Cancer Hospital, shares results from a phase I trial of SHR2554, an oral, small molecule EZH2 inhibitor, in patients with R/R PTCL (N = 67). The primary endpoint was met, with an ORR of 64.2%. A phase III trial

CONGRESS | #EHA2025 | PRESENTATION Daniel Kerr, Tampa General Hospital Tampa General Cancer Institute, presents updated results from the epcoritamab + pola-R-CHP cohort of the phase Ib/II EPCORE NHL-5 trial (N = 37). Fixed-duration epcoritamab + pola-R-CHP in patients with newly diagnosed

CONGRESS | #EHA2025 | PRESENTATION Thomas Melchardt, Paracelsus Medical University, Salzburg Cancer Research Institute, and Austrian Group for Medical Tumor Therapy, shares initial results from a phase II trial assessing rituximab-polatuzumab-glofitmab (R-Pola-Glo) in previously

CONGRESS | #EHA2025 | POSTER Justin Darrah, Cedars-Sinai Medical Center shares the results of a match-adjusted comparative analysis demonstrating the benefit of adding epcoritamab to R-DHAX/C or R-ICE vs chemoimmunotherapy regimens alone in pts with R/R DLBCL intended for

CONGRESS | #EHA2025 | PRESENTATION Viola Pöschel, Universität Saarland Saarland University Medical School, highlights results from a phase III trial assessing interim PET adapted treatment reduction in elderly patients with DLBCL with a favorable prognosis (N = 288). PET-4 adapted treatment

CONGRESS | #EHA2025 | PRESENTATION Talha Munir, LeedsCancerCentre, shares findings from the FLAIR study of MRD-guided Ibr+Ven vs Ibr monotherapy vs FCR in CLL (N=786). Ibr+Ven demonstrated superiority of PFS (93.9% vs 58.1% vs 79.0%) and OS (95.9% vs 86.5% vs 90.5%) compared to FCR

CONGRESS | #EHA2025 | PRESENTATION Paolo Ghia, Università Vita-Salute San Raffaele, Ospedale San Raffaele, presents the final analysis from the CAPTIVATE study of Ibr+Ven for CLL/SLL (N=202, FD cohort n=159; MRD cohort n=43). 5.5-year PFS=66% and OS=97%. In the FD cohort, 5.5-year PFS among patients without vs

CONGRESS | #EHA2025 | PRESENTATION Lydia Scarfò, Lydia Scarfò, Università Vita-Salute San Raffaele, Ospedale San Raffaele presents updated data from the ongoing CaDAnCe-101 study of BGB-16673 in R/R CLL/SLL (N=66). Overall ORR=84.8%; ORR (200-mg group)=93.8%, 12-month PFS=77.4%. BGB-16673 was well tolerated, with

CONGRESS | #EHA2025 | PRESENTATION Chan Cheah, Chan Cheah, UWA, North Metropolitan Health Service, presents updated phase I trial data from the R/R CLL/SLL cohort treated with sonrotoclax+zanubrutinib (N=47). Sonrotoclax+zanubrutinib 320 mg cohort demonstrated high efficacy and safety with

CONGRESS | #EHA2025 | POSTER Paolo Ghia, Università Vita-Salute San Raffaele, presented findings from an exploratory analysis of the phase III AMPLIFY trial (ACE-CL-311; NCT03836261) evaluating MRD kinetics and the relationship between MRD status and PFS in treatment-naïve patients with CLL (N = 867)

CONGRESS | #EHA2025 | POSTER Astrid Pavlovsky presented long-term findings from the GATLA LH-05 trial evaluating PET-CT-adapted treatment following 3 cycles of ABVD in patients with classical Hodgkin #lymphoma (N = 557). PET3-negative patients had significantly better PFS at 60

It’s been a busy month for the #Lymphoma Hub! Tomorrow, we’ll be covering the 18th ICML. 📅 June 17–21 📍 Lugano, CH Keep an eye on our socials for live coverage. Thank you to Sobi and AbbVie for making this possible. #lymsm #18ICML

🚨 NEWS 🚨 The U.S. FDA has approved the tablet formulation of zanubrutinib for all five approved indications, including CLL/SLL, WM, MCL (after failure of ≥1 LOT), MZL (after failure of ≥1 anti-CD20-based regimen), and FL after failure of ≥2 LOT. Read more here:

During #EHA2025, Marek Trneny, Charles University, shared the first results from the EPCORE NHL-2 trial of epcoritamab + R-ICE in patients with R/R DLBCL eligible for ASCT. Watch the full video and read more here: loom.ly/LbVZMbc #lymsm #lymphoma

Catch up on the latest developments in lymphoma and CLL from #18ICML with our live social media coverage. loom.ly/Pc0ysis #lymphoma #lymsm

During #EHA2025, Gareth Gregory, Monash University, shares the latest updates from the STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL. Watch the full video and read more here: loom.ly/f2O-o_4 #lymsm #lymphoma